---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-005503"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:46:35.461364+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agenus Q2 net loss narrows to $49M; botensilimab shows 24% ORR in MSS CRC

## Summary
- Net loss of $49.2M ($0.17/share) vs $84.0M ($0.37) in Q2 2021; revenue $20.9M (up from $10.7M).
- Cash & investments $238M at June 30, 2022, down from $307M at Dec 31, 2021.
- Botensilimab/balstilimab combo achieved 24% ORR and 73% DCR in 41 heavily pretreated MSS CRC patients.
- Phase 2 randomized trials in MSS CRC, melanoma, and pancreatic cancer to start later this year.
- First patient dosed in Phase 1 study of AGEN1571 (anti-ILT2) in advanced solid tumors.

## SEC filing metadata
- accession: 0001171843-22-005503
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000117184322005503/0001171843-22-005503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000117184322005503/f8k_080922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-005503
- JSON: https://secwatch.observer/filing/0001171843-22-005503.json
- Plain text: https://secwatch.observer/filing/0001171843-22-005503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.